MALT Lymphoma: Many Pathways Lead to NF-κB Activation

被引:0
|
作者
Du, M. Q. [1 ]
机构
[1] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England
来源
JOURNAL OF PATHOLOGY | 2013年 / 229卷
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:S4 / S4
页数:1
相关论文
共 50 条
  • [31] NF-κB pathways in hematological malignancies
    Chiara Gasparini
    Claudio Celeghini
    Lorenzo Monasta
    Giorgio Zauli
    Cellular and Molecular Life Sciences, 2014, 71 : 2083 - 2102
  • [32] Crosstalk in NF-κB signaling pathways
    Andrea Oeckinghaus
    Matthew S Hayden
    Sankar Ghosh
    Nature Immunology, 2011, 12 : 695 - 708
  • [33] The Accomplices of NF-κB Lead to Radioresistance
    Bai, Miaomiao
    Ma, Xiaoxing
    Li, Xiaolei
    Wang, Xiaohui
    Mei, Qian
    Li, Xiang
    Wu, Zhiqiang
    Han, Weidong
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2015, 16 (04) : 279 - 294
  • [34] Malt1 and cIAP2-Malt1 as effectors of NF-κB activation: Kissing cousins or distant relatives?
    Kingeter, Lara M.
    Schaefer, Brian C.
    CELLULAR SIGNALLING, 2010, 22 (01) : 9 - 22
  • [35] NF-κB mediates aberrant activation of HIF-1 in malignant lymphoma
    Qiao, Qiao
    Nozaki, Yumi
    Sakoe, Kumi
    Komatsu, Norio
    Kirito, Keita
    EXPERIMENTAL HEMATOLOGY, 2010, 38 (12) : 1199 - 1208
  • [37] Activation of classical and noncanonical NF-κB pathways in renal cortex of diabetic mice
    Tilton, RG
    Fouladi, NN
    Haidacher, S
    Lejeune, W
    Tieu, BC
    Denner, LA
    DIABETES, 2005, 54 : A208 - A208
  • [38] Signalling loops and linear pathways: NF-κB activation in response to genotoxic stress
    Brzoska, Kamil
    Szumiel, Irena
    MUTAGENESIS, 2009, 24 (01) : 1 - 8
  • [39] EBV LMP1: New and shared pathways to NF-κB activation
    Lavorgna, Alfonso
    Harhaj, Edward W.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (07) : 2188 - 2189
  • [40] The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy
    Lin, Yong
    Bai, Lang
    Chen, Wenjie
    Xu, Shanling
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (01) : 45 - 55